Works from 2024
PACE: A randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4/6 inhibitor and aromatase inhibitor for hormone receptor-positive/human epidermal growth factor receptor-negative metastatic breast cancer, Erica L. Mayer, Yue Ren, Nikhil Wagle, et al. (Article)
Urinary bother, urinalysis, and two-year efficacy follow-up results of phase I trial of intravesical bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous bacillus Calmette-Guérin treatment, Jazzmyne Montgomery, Daniel Lybbert, Sherjeel Sana, et al. (Article)
Comparison of intermittent intravenous tacrolimus to continuous tacrolimus in adult allogeneic stem cell transplant recipients, Michael Williams, Zartash Gul, Justin Graff, et al. (Article)
Abstract PO4-09-11: Predictors of cardiotoxicity in early breast cancer patients treated with Doxorubicin and/or Trastuzumab: Implications of race/ethnicity and insurance status, Shahzaad Jahangier, Rubina Qamar, Vinay Thohan, et al. (Abstract)
Abstract PO5-15-01: Prospective biomarker assessment of cardiotoxicity among ethnically diverse women with early breast cancer, Shahzaad Jahangier, Rubina Qamar, Maharaj Singh, et al. (Abstract)
Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, version 2023.3, Ishmael A. Jaiyesimi, Natasha B. Leighl, Michael Mullane, et al. (Article)
Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO Living Guideline, version 2023.3, Ishmael A. Jaiyesimi, Natasha B. Leighl, Michael Mullane, et al. (Article)
Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study, Mara Serena Serafini, Carolina Reduzzi, Rubina Qamar, et al. (Abstract)
Systemic therapy for breast cancer, Sigrun Hallmeyer, Rubina Qamar, and Corey J. Shamah (Book Chapter)
Works from 2023
Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study, Lorenzo Gerratana, Yue Ren, Rubina Qamar, et al. (Abstract)
Incidence of cardiac events in patients with MDS or AML receiving azacitidine or decitabine within a large community health system, Noor Naffakh, Michael Williams, Priyam Patel, et al. (Abstract)
Reduced blood product utilization via implementation of an anemia clinic and consult service in a large health system hospital, Reid Christian Bowers, Sandra Tomany Korman, Michael A. Thompson, et al. (Abstract)
Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI), Anna Couvillon, Baris Turkbey, Michael P. Mullane, et al. (Abstract)
Characteristics of patients with hematologic malignancies without seroconversion post-COVID19 third vaccine dosing, Sigrun Hallmeyer, Michael A. Thompson, Veronica Fitzpatrick, et al. (Article)
Works from 2022
Quantifying the value of the molecular tumor board: Discordance recommendation rate and drug cost avoidance, Mary K. Walters, Andrew T. Ackerman, James L. Weese, et al. (Article)
Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL, Zaid Al-Kadhimi, Samuel Pirruccello, Zartash Gul, et al. (Letter)
Recurrent venous thromboembolism in a patient with nephrotic syndrome on rivaroxaban therapy, Dorota Magdon and Magdalena Flejsierowicz (Poster)
Vitamin B12 deficiency as unexpected cause of hemolytic anemia and atypical presentation of hepatocellular adenoma, Andrew Gregory and Magdalena Flejsierowicz (Poster)
Management of metastatic clear cell renal cell carcinoma: ASCO guideline, W Kimryn Rathmell, R Bryan Rumble, Peter J. Van Veldhuizen, et al. (Article)
Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies, Michael A. Thompson, Sigrun Hallmeyer, Veronica E. Fitzpatrick, Yunqi Liao, Michael P. Mullane, Stephen C. Medlin, Kenneth Copeland, and James L. Weese (Original Research)
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial, Tait D. Shanafelt, Xin Victoria Wang, Curtis A. Hanson, et al. (Article)
Characteristics of patients with hematologic malignancies without seroconversion post-COVID19 third vaccine dosing (3V): Real-world data from large midwestern healthcare system, Sigrun Hallmeyer, Michael A. Thompson, Veronica Fitzpatrick, et al. (Abstract)